Tim Leiner1, Suzanne Gerretsen1, Thierry le Maire2, Stephan Miller3, Siegfried Thurnher4, Christoph U. Herborn5, Henrik Michaely6, Harald Kramer7, Angelo Vanzulli8, Josef Vymazal9, Martin Wasser10
1Department of Radiology, Maastricht
University Hospital, Maastricht, Netherlands; 2Department of
Radiology, Catharina Hospital, Eindhoven, Netherlands; 3Department
of Diagnostic and Interventional Radiology, Eberhard-Karls University,
Tbingen, Germany; 4Department of Radiology, Hospital of St. John's
of God, Vienna, Austria; 5Medical Prevention Center, University
Medical Center, Hamburg-Eppendorf, Germany; 6Department of Clinical
Radiology, University Hospital Mannheim, Mannheim, Germany; 7Institute
of Clinical Radiology, Ludwig Maximilians University, Munich, Germany; 8Radiologia,
Ospedale Niguarda Ca' Granda, Milan, Italy; 9Department of
Radiology,, Homolce Hospital, Prague, Czech Republic; 10Department
of Radiology, Leiden University Medical Center, Leiden, Netherlands
This study intraindividually compared 0.1 mmol/kg bodyweight doses of
gadobenate dimeglumine (MultiHance; Gd-BOPTA) and gadopentetate dimeglumine
(Magnevist; Gd-DTPA) for contrast-enhanced MRA in 96 patients with peripheral
arterial occlusive disease. Preference for Gd-BOPTA was expressed by each of
three off-site blinded readers for all qualitative endpoints in each of three
vascular territories. Likewise significantly (p≤0.0001) higher CNR was
noted for Gd-BOPTA by each reader in each vascular territory. Overall, Gd-BOPTA
at 0.1 mmol/kg demonstrated significantly better diagnostic performance
compared to an equivalent dose of Gd-DTPA for CE-MRA of the peripheral vasculature.